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Abstract 
Gynostemma pentaphyllum (Thunb.) Makino (GpM) (Jiaogulan) has been widely used in Chinese medicine for the 
treatment of several diseases, including hepatitis, diabetes and cardiovascular disease. Furthermore, GpM has recently 
been shown to exhibit potent anti-cancer activities. In this review, we have summarized recent research progress on 
the anti-cancer activities and mechanisms of action of GpM, as well as determining the material basis for the anti-can-
cer effects of GpM by searching the PubMed, Web of Science and China National Knowledge Infrastructure databases. 
The content of this review is based on studies reported in the literature pertaining to the chemical components or 
anti-cancer effects of GpM up until the beginning of August, 2016. This search of the literature revealed that more 
than 230 compounds have been isolated from GpM, and that most of these compounds (189) were saponins, which 
are also known as gypenosides. All of the remaining compounds were classified as sterols, flavonoids or polysaccha-
rides. Various extracts and fractions of GpM, as well as numerous pure compounds isolated from this herb exhibited 
inhibitory activity towards the proliferation of cancer cells in vitro and in vivo. Furthermore, the results of several 
clinical studies have shown that GpM formula could have potential curative effects on cancer. Multiple mechanisms of 
action have been proposed regarding the anti-cancer activities of GpM, including cell cycle arrest, apoptosis, inhibi-
tion of invasion and metastasis, inhibition of glycolysis and immunomodulating activities.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Cancer is the world’s leading cause of death, accounting 
for 8.2 million deaths in 2012, and it is expected that the 
annual number of global cancer cases will rise from 14 mil-
lion in 2012 to 22 million within the next two decades [1]. 
The isolation and evaluation of anti-cancer agents and lead 
compounds from natural resources represents a traditional 
and effective approach for the development of new drugs 
for the treatment of cancer [2, 3], as exemplified by Pacli-
taxel, which was derived from Taxus brevifolia [3, 4].
Gynostemma pentaphyllum (Thunb.) Makino (GpM) 
(Jiaogulan) has been widely used in Chinese medicine 
for the treatment of various diseases, including hepati-
tis, diabetes and cardiovascular disease. Modern medi-
cal research has shown that GpM exhibits a variety of 
pharmacological properties, including anti-inflammatory 
[5–8], antioxidative [9–13], lipid metabolism regulatory 
[14–18], antiproliferative [19–22], neuroprotective [23, 
24] and anxiolytic activities [25–27]. GpM has conse-
quently been widely used for the treatment of hepatitis 
[15, 28–30], diabetes [11, 30–32], cardiovascular disease 
[33–35] and cancer [20, 23, 36, 37]. GpM is also widely 
used as a health supplement in beverages, biscuits, noo-
dles, face washes and bath oils [38–41].
We have conducted a comprehensive review of the lit-
erature associated with GpM to provide a summary of 
recent research towards the anti-cancer activities and 
mechanisms of action of GpM. We have also searched the 
PubMed, Web of Science and China National Knowledge 
Infrastructure (CNKI) databases to identify the material 
basis for the anti-cancer effects of GpM.
Literature search strategy and exclusion criteria
Our literature search covered all of the records in the 
PubMed, Web of Science Core Collection and CNKI 
databases up until the beginning of August, 2016. All of 
the studies included in this review reported on either the 
chemical components or the anti-cancer effects of GpM. 
The following search strategy was used to search PubMed 
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with the “All Fields” option and the Web of Science Core 
Collection in the “Topic” field (Table  1). Studies were 
excluded if they were: (a) duplicated; (b) not pertinent 
to the chemical components or the anti-cancer effects of 
GpM; or (c) not full-text journal articles.
Clinical studies were not excluded from the searches 
conducted using the PubMed and Web of Science data-
base; however, no records involving clinical trials were 
found in either of these databases. For this reason, we 
searched the CNKI database for clinical studies pertain-
ing to the use of GpM for the treatment of cancer. The 
following search strategy was used to search the CNKI 
database using the “Abstract” field (Table 2). Studies were 
excluded from the results if they were: (a) not pertinent 
to the clinical anti-cancer effects of GpM; (b) review arti-
cles; or (c) not full-text journal articles.
Two reviewers independently searched the databases 
and screened all of the articles for their eligibility. The 
search strategies and selection processes used by the 
reviewers are shown in Fig. 1. In this way, we identified 
108 articles, which have been included in this review.
Chemical components of GpM
Over 230 compounds have been identified as being 
derived from GpM and can be grouped according to their 
chemical structures into saponins, sterols, flavonoids, 
polysaccharides and several other compound classes.
Saponins
One hundred and eighty-nice saponins, which are also 
known as gypenosides (Gyps), have been isolated from 
GpM and fully characterized using spectroscopic meth-
ods [42–45]. At the 23rd meeting of the Japanese society 
of pharmacognosy, Nagai et al. [46] reported the isolation 
of two dammarane-type saponins, including panoxadiol 
and 2α-OH-panoxadiol, from the hydrolysate of Gyps. 
The research groups of Takemotoet [47–50] and Yoshi-
kawa [51, 52] subsequently reported the isolation and 
characterization of many other Gyps from GpM. Gyps 
are the major components of GpM, and mainly consist 
of triterpenoid saponins, which can be purified from 
ethyl acetate or n-butanol extracts [53]. One hundred 
and sixty-five of the 189 Gyps reported to date have been 
grouped into 12 classes based on the nature of their agly-
cone moiety [43]. However, the remaining 24 Gyps [44, 
45, 54–60] do not belong to any of these classes. The gen-
eral structure of Gyps is shown in Table 3, and shows that 
these compounds consist of a hydrophobic sapogenin 
moiety (where R1  =  hydrocarbon chain with or with-
out double bond(s), cyclopentane, oxacyclopentane or 
some other group) and a hydrophilic sugar group (where 
R4 = glucose, rhamnose or xylose).
Sterols
Sterols are composed of 17 carbon atoms across four rings, 
i.e., three 6-carbon rings and a single 5-carbon ring, with 
a side chain extending from C17 containing nine or ten 
carbon atoms (Additional file 1: Table S1). Eighteen ster-
ols were isolated from GpM and fully characterized using 
a unique method from 1986 to 1990 [61–67]. Briefly, GpM 
was extracted with CH2Cl2, and the extracted lipids were 
saponified with 5 % KOH in MeOH. After purification by 
column chromatography over silica gel, the sterol mix-
ture was acetylated, crystallized and characterized using 
spectroscopic methods. This process resulted in the isola-
tion of sterols with ergostane, cholestane and stigmastane 
skeletons. The structures of these 18 sterols are shown in 
Additional file  1: Table S1. These compounds contained 
one double bond between C5–C6, C7–C8 or C9–C11, 
with R2 = H or CH3 and R1 = hydrocarbon chain with 10 
carbons, and one double bond or one alkynyl group.
Polysaccharides
Polysaccharides are major components of GpM, where 
they are typically conjugated with proteins [68]. The 
Table 1 Strategy in searching PubMed and Web of Science
Step Search terms Citations reviewed
PubMed Web of Science
1 Gynostemma pentaphyllum 280 314
2 Jiaogulan 284 22
3 Gypenoside 137 96
4 Constituents 58,058 137,552
5 Composition 328,924 780,071
6 Components 471,244 1,371,871
7 Tumor 3,285,652 983,570
8 Cancer 3,336,622 1,467,455
9 Carcinoma 797,702 521,059
10 1 or 2 or 3 322 364
11 4 or 5 or 6 821,820 2,163,770
12 7 or 8 or 9 3,699,522 2,049,723
13 10 and 11 66 109
14 10 and 12 81 83
15 13 or 14 130 162
Table 2 Strategy in searching CNKI
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molecular weight of the polysaccharides found in GpM 
varies from 9000 to 33,000  Da [69]. Several different 
kinds of polysaccharides have been found in GpM, and 
the molar ratios of the monosaccharide components of 
these systems have been reported to vary considerably. 
For instance, the neutral polysaccharide fraction CGPP 
mainly consists of mannose, glucose, arabinose, rham-
nose, galactose and glucuronic acid with molar ratios 
of 2.0:2.2:1.3:2.2:1.2:2.5 [20]. Another polysaccharide 
fraction (NaCl eluted fraction of crude polysaccharides 
from GpM by DEAE-Sepharose CL-6B chromatogra-
phy, GMC) consisted of glucose, galactose, mannose 
and fructose with the molar ratios of 1:2.17:1.25:1.02 
[70]. Furthermore, the water-soluble GpM polysac-
charide fraction GP-I contains glucose, galactose, 
mannose, rhamnose and arabinose with molar ratios 
of 5.3:4.2:3.0:0.7:0.8 [69]. Based on the differences in 
the possible arrangements of the monosaccharides, 
various polysaccharides have been isolated from GpM 
[71].
Fig. 1 Flowchart indicating the search strategies and processes used in this study
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Table 3 Structures and in vitro anti-cancer activity of identified GpM components
Compd R1 R2 R3 R4 R5 R6 Anti-cancer activity
a Reference
1 H H CH3 H 47.12 (HL-60) [122]
2 H H CH3 H 45.50 (HL-60) [122]
3 H H CH3 H HL-60, Colon 205, Du145, GC-7901, BEL-7402 [85, 86]
4 H H CH3 H HL-60, Colon 205, Du145, GC-7901, BEL-7402 [85, 86]
5 H H CHO H HL-60, Colon 205, Du145, GC-7901, BEL-7402 [85, 86]
6 H H CHO H HL-60, Colon 205, Du145, GC-7901, BEL-7402 [85, 86]
7 CH3 H CHO H HL-60, Colon 205, Du145, GC-7901, BEL-7402 [85, 86]
8 CH3 H CHO H HL-60, Colon 205, Du145, GC-7901, BEL-7402 [85, 86]
9 CH3 H CH3 H HL-60, Colon 205, Du145, GC-7901, BEL-7402 [85, 86]
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Table 3 continued
Compd R1 R2 R3 R4 R5 R6 Anti-cancer activity
a Reference
10 CH3 H CH3 OH 67.66 ± 3.36 (HL-60), 18.45 ± 0.93 (MCF-7),  
34.95 ± 0.93(HT-29), 20.97 ± 1.49 (A549), 27.68 ± 1.58  
(SK-OV-3)
[53]
11 CH3 H CH3 =O >109.2 (HL-60), 42.81 ± 3.60 (MCF-7), 22.06 ±  
2.18 (HT-29), 31.45 ± 2.62 (A549), 30.25 ± 1.53 (SK-OV-3)
[53]
12 CH3 H CH3 =O >107.6 (HL-60), 23.03 ± 1.40 (MCF-7), 46.30 ±  
1.08 (HT-29), 21.09 ± 1.18 (A549), 35.62 ± 0.97 (SK-OV-3)
[53]
13 CH3 H CH3 =O 76.63 ± 2.98 (HL-60), 23.62 ± 1.02 (MCF-7),  
39.34 ± 1.02 (HT-29), 19.90 ± 1.40 (A549), 19.90 ±  
1.49 (SK-OV-3)
[53]
14 H H CH3 H 7.44 (HL-60), 27.80 (Colon 205), 24.12 (Du145) [127]
15 H H H CH3 H 3.90 (MDA-MB-435) [128]
16 H H H CH3 H 0.05 ± 0.01 (A549), 0.25 ± 0.07 (U87) [129]
17 H OH H CH3 OH 12.54 ± 0.53 (A549) [130]
18 H OH CH3 OH 34.94 ± 4.23 (A549) [130]
19 H H H CH3 H 40 ± 0.7 (HepG2) [44]
20 H H H CH3 OH 38 ± 0.5 (HepG2) [44]
Page 6 of 16Li et al. Chin Med  (2016) 11:43 
Table 3 continued
Compd R1 R2 R3 R4 R5 R6 Anti-cancer activity
a Reference
21 H H H CH3 H 41.89 (HCT116), 20.94 (HT-29), 32.61 (MCF-7) [55]
22 H H H CH3 H 41.40 (HCT116), 19.00 (HT-29), 28.82 (MCF-7) [55]
23 H H CHO H 32.00 ± 1.24 (HepG2) [56]
24 H H CH3 H 21.38 ± 1.06 (HepG2) [56]
25 H OH CH3 OH 74.3 ± 1.9 (A549) [59]
26 18.41 (HT-29), 4.46 (MCF-7), 9.39 ± 0.9  
(DI145), 6.93 ± 0.5 (22RV-1)
[54, 55]
27 20.38 (HT-29), 13.51 (MCF-7) [55]
28 16.14 (HT-29), 8.84 (MCF-7) [55]
Flavonoid fraction 33.3 (PC-3) [21]
Carotenoid fraction 1.6 (Hep3B) [84]
Chlorophyll fraction 57.5 (Hep3B) [84]
Nonpolar fraction 38.02 ± 2.98 (MDA-MB-453), 31.62 ± 1.76 (HCT116), 
35.48 ± 3.81 (LNCaP), 35.48 ± 6.45 (MCF7)
[22]
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Flavonoids
Flavonoids are an important class of polyphenol com-
pounds that are widely distributed in fruits and veg-
etables, where they usually exist in their glycosidic form 
[72]. In terms of their general structure, flavonoids con-
sist of a 15-carbon skeleton, containing two phenyl rings 
(A and B) and a heterocyclic ring (C). The carbon struc-
ture of these compounds is usually abbreviated as C6–
C3–C6. Several flavonoids have been isolated from GpM, 
including quercetin, rutin, ombuoside [73], ombuin [74], 
isorhamnetin-3-O-rutinoside, isorhamnetin [75], querce-
tin-di-(rhamno)-hexoside, quercetin-rhamno-hexoside, 
kaempferol-rhamno-hexoside and kaempferol-3-O-ruti-
noside [76], and the structures of these flavonoids are 
shown in Additional file 1: Table S2.
Other components of GpM
GpM contains various trace elements (e.g., Cu, Fe, Zn, 
Mn, Co, Ni, Se, Mo and Sr) [77], 18 amino acids [78] 
(including eight essential amino acids) and various vita-
mins and proteins, but the relative amounts of these 
components vary considerably across the different parts 
of the GpM plant (i.e., leaf, stem and subterranean stem) 
[78]. Malonic acid [74], benzyl-O-β-d-glucopyranoside 
[79], lutein, vomifoliol, palmitic acid [80], linolenic acids 
[81, 82] and carrot glycosides [83] have also been iso-
lated from GpM. Furthermore, Tsai et  al. [84] reported 
the isolation of numerous carotenoids and chlorophylls 
from the carotenoid and chlorophyll fractions of GpM, 
respectively.
Anti-cancer activities of GpM
In vitro anti‑cancer activities of GpM
The in vitro antiproliferative activities of some of the pure 
compounds and extracts isolated from GpM have been 
widely reported and the details of these materials are 
summarized in Table 3. Shi et al. [85] obtained four dam-
marane-type triterpene saponins (compounds 3–6) from 
the aerial parts of GpM, which exhibited moderate cyto-
toxic activities in vitro against several human cancer cell 
lines, including HL-60 (human promyelocytic leukemia 
cells), Colon 205 (human colon cancer cells) and Du145 
(human prostate carcinoma cells) cells. Yin et  al. [86] 
isolated nine dammarane saponins from the methanol 
extract of the aerial part of GpM, and found that com-
pounds 7, 8 and 9 exhibited inhibitory activities towards 
the growth of SGC-7901 (stomach cancer cells) and BEL-
74020 (hepatocellular carcinoma cells) at a concentration 
of 100 μM with percentage inhibition values of 21, 93 and 
8 %, and 77, 92 and 40 %, respectively.
Almost all of the compounds and extracts isolated from 
GpM to date have be reported to exhibit noticeable anti-
proliferative activities with IC50 values ranging from 0.05 
to 74.3 μg/mL (Table 3). Compound 16 exhibited potent 
antiproliferative activities against A549 human lung can-
cer cells and U87 glioblastoma cells with IC50 values of 
0.05 and 0.25 μg/mL, respectively. Compound 15 showed 
antiproliferative activity against MDA-MB-435 human 
breast cancer cells with an IC50 value of 3.90  μg/mL, 
whereas the carotenoid fraction of GpM exhibited the 
strongest activities of all of the reported extracts with an 
Table 3 continued
Compd R1 R2 R3 R4 R5 R6 Anti-cancer activity
a Reference
Gypenosides 47.6 (Hep3B), 39.3 (PC-3), 30.6 (A549) HL-60, MCF-7,  
HT-29, Colon 205, Du145, MDA-MB-435, U87, A549,  
SK-OV-3, HepG2, SGC-7901, BEL-7402, Huh-7, HA22T,  
SW620, Eca-109, SAS, L1210, WEHI-3, SW-480, KB/VCR,  
MCF-7/ADR
[19, 21, 36, 44, 
85–87, 89–91, 
105–109, 111, 
112, 114, 115, 
119, 121, 131, 
132]
Polysaccharide 65.4 (B16), HT-29, B16, Hela, SW-1116, HepG2 [44, 87, 88, 119]
Ethanolic extract C6, HT-59 [113, 133]
a The anti-cancer activities, IC50 (μg/ml), of components of GpM are expressed as mean ± SD following cell line names in bracket. Only the mean value is listed if there 
is no SD value available and only cancer cell line name is listed if no IC50 data is available. The unit of compound 10, 11, 12, 13, 16, 21, 22, 26, 27 and 28 are transformed 
based on molecular weight. This table also presents 30 cancer cell lines whose proliferation could be inhibited by GpM, which indicates that GpM exerts broad 
spectrum anti-cancer activities
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IC50 value of 1.6 μg/mL against Hep3B human hepatocel-
lular carcinoma cells.
The hydrolysates of the extracts of GpM have also been 
reported to exhibit anti-cancer activities, together with 
several other derivatives of the natural products found in 
GpM. For example, Chen et al. [87] reported the synthe-
sis of four sulfated derivatives of GPP2, which is a native 
polysaccharide isolated from GpM. One of the sulfated 
derivatives prepared by Chen (GPP2-s4) inhibited the 
growth of HepG2 human hepatocellular carcinoma cells 
by 46.4 ± 2.8 % at a concentration of 2000 μg/mL. Com-
pared with GPP2, all four sulfated derivatives exhibited 
stronger antiproliferative activities against HeLa cervi-
cal cancer cells at concentrations as low as 100  μg/mL. 
GP-B1, which is an acidic polysaccharide derived from 
GpM, significantly inhibited the growth of B16 mela-
noma cells with an IC50 of 65.4  μg/mL with very little 
cytotoxicity against normal cells [88]. Moreover, GP-B1 
not only significantly inhibited the growth of cancer 
cells, but also improved cellular immune response by 
increasing levels of tumor necrosis factor-α (TNF-α), 
interferon-γ (IFN-γ), interleukin-10 (IL-10) and inter-
leukin-12 (IL-12) observed in the serum of melanoma-
B16-bearing mice [88].
In vivo anti‑cancer activities of GpM
The in  vivo anti-cancer activities of GpM are summa-
rized in Table  4. Gyps led to significant reductions in 
the size of solid tumors in nude mice injected with SAS 
oral cancer cells [89]. Gyps also promoted the survival 
of mice xenografted with WEHI-3 leukemia cells, which 
was accompanied by an increase in the number of mega-
karyocytes and reduced spleen weight in these animals, 
indicating an enhanced immune response [90]. Similar 
anti-cancer activities have also been reported for Gyps 
in another leukemia mouse model [91]. The intraperito-
neal treatment of tumor-bearing mice with Gyps (5 or 
20 mg/kg/day) for 4 weeks led to considerable decreases 
in the size and weight of their tumors without alter-
ing their body weight. Gyps also strongly suppressed 
tumor growth in mice bearing advanced S180 sarcoma, 
which was associated with an increase in the ratio of 
tumor necrosis area to tumor total area and lympho-
cyte/macrophage infiltration into the peripheral areas of 
tumors. This effect also led to an increase in the weight 
of the spleens of these animals, as well as increases in 
the quantity and size of their splenic white pulp [92]. 
Gyps enhanced the anti-cancer effects of 5-fluorouracil 
in colorectal cancer cells and xenografts [93]. Gyps have 
also been reported to inhibit tumorigenesis in a trans-
genic mouse models of cancer, such as the ApcMin/+ 
mouse model of intestinal neoplasia [94, 95]. Moreo-
ver, rats fed with a standardized extract of GpM did not 
show any mortal or toxic effects, highlighting the good 
safety profile of this material [96].
A polysaccharide from GpM inhibited the develop-
ment of transplanted S180 sarcoma in a dose-dependent 
manner and increased the phagocytosis of macrophages, 
as well as increasing the production of NO, IL-1β and 
TNF-α from the peritoneal macrophages [97]. The neu-
tral polysaccharide fraction CGPP inhibited the growth 
of H22 hepatocarcinoma cells transplanted into ICR 
mice [20]. CGPP treatment also led to improvements 
in the body weight, spleen/thymus index and degree of 
splenocyte proliferation in tumor-bearing mice [20]. Fur-
thermore, CGPP treatment led to considerable increases 
in the levels of cytokines, such as IL-2, TNF-α and IFN-γ 
in tumor-bearing mice, as well as increases in the activity 
of natural killer (NK) cells and cytotoxic T lymphocytes 
(CTL) [20]. The tumor inhibitory and immunoregulatory 
effects of CGPP greatly increased the life span of H22 
ascites in tumor-bearing mice [20].
Clinical anti-cancer studies on GpM
A clinical study was conducted in 1993 involving 59 
patients with advanced malignant tumors to assess the 
effects of GpM [98]. The results revealed that patient 
treated with a GpM formula showed cancer relapse and 
metastasis rates of 11.9 and 8.5 %, respectively, compared 
with values of 72.4 and 55.2 % in the control group. The 
results of this study also revealed that the T lymphocyte 
transformation rate and acid α-naphthyl acetate ester-
ase (ANAE+) activity increased by 8.2 % following GpM 
treatment [98]. The results of a separate 5-year obser-
vational study also showed that the treatment of cancer 
patients with GpM formula led to significant reductions 
in cancer relapse and metastasis rates, as well as reduced 
mortality and improved immune function in these 
patients [99]. GpM has also been reported to enhance NK 
cell activity in breast cancer patients [100], and improve 
the immune function of cancer patients after chemother-
apy, as demonstrated by increased T lymphocyte trans-
formation rate and decreased IgG and IgM levels [101]. 
Furthermore, GpM enhanced the immunological func-
tion of lung cancer patients after chemotherapy [102]. 
The results of a recent study [103] demonstrated that 
GpM formula can work in synergy with chemotherapy 
reagents. The clinical uses of GpM are summarized in 
Table 5.
Mechanisms of action
Multiple mechanisms of action have been proposed 
regarding the anti-cancer activities of GpM, including 
cell cycle arrest, apoptosis induction, inhibition of inva-
sion and metastasis, glycolysis inhibition and immu-
nomodulation (Fig. 2).
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Cell cycle arrest
Gyps induced cell cycle arrest at the G0/G1 phase SAS 
human oral cancer cells [89], WEHI-3 leukemia cells 
[90], A549 human lung adenocarcinoma cells [104], 
HL-60 human myeloid leukemia cells [91] and Colo 205 
human colon cancer cells [105]. Gyps also induced cell 
cycle arrest by modulating the expression of several cell 
cycle regulatory proteins, including cyclin-dependent 
kinase 2 (CDK2), cyclin-dependent kinase 4 (CDK4) and 
cyclin-dependent kinase 6 (CDK6) [21, 106]. The treat-
ment of SCC-4 human tongue cancer cells with Gyps 
induced checkpoint kinase 2 (Chk2) expression. This 
effect subsequently led to the upregulation of p53 and 
its targets p21 and p16, which led to decreased levels of 
cyclin D and cyclin E and G0/G1 cell cycle arrest [106]. 
The treatment of PC-3 human prostate carcinoma cells 
with flavonoids and saponins isolated from GpM led to 
cell cycle arrest in the S and G2/M phases in both cases 
by modulating the expression of cyclins [21]. Further-
more, A549 cells treated with flavonoids from GpM 
went into cell cycle arrest in the S and G2/M phases, and 
showed upregulated levels of Cyclin A, Cyclin B, p21 and 
p53 [24].
Induction of apoptosis
A large number of studies have shown that GpM exerts 
its anti-cancer activities by inducing cellular apoptosis 
through various signaling pathways. Gyps downregulated 
the anti-apoptotic proteins Bcl-2 and Bcl-xL, and upreg-
ulated the pro-apoptotic proteins Bax, Bad and Bak, 
thereby activating the formation of Bax/Bak pores on the 
outer mitochondrial membrane [89–91, 107, 108]. Bax/
Bak pores allow for the release of cytochrome c and other 
pro-apoptotic proteins into the cytosol, leading to the 
activation of initiator caspases-8 and -9, followed by the 
cleavage of effector caspase-3, which ultimately triggers 
apoptosis [104–106]. The formation of Bax/Bak pores fol-
lowing Gyps treatment also led to the release of apoptosis 
inducing factor (AIF) and endonuclease G (EndoG) from 
the mitochondria [89, 106], following DNA fragmenta-
tion and chromatin condensation.
Gyps also induced the production of reactive oxy-
gen species (ROS) [36, 89, 105, 106, 108, 109] and led 
to increased intracellular Ca2+ concentrations [89–91, 
105, 106, 108]. ROS and Ca2+ are both well-studied 
modulators of the permeability transition pores located 
on the inner mitochondrial membrane. The opening 
of these pores leads to an influx of solutes and water 
into the mitochondrial matrix, causing the outer mito-
chondrial matrix to swell and rupture, which leads 
to the release of cytochrome c and apoptosis [89–91, 
105–107]. Gyps treatment led to increased levels of 
DNA-damage-inducible transcript 3 (GADD153), glu-
cose-regulated protein (GRP78), activating transcription 
factor 6 alpha (ATF6-α) and activating transcription fac-
tor 4 alpha (ATF4-α). These increases resulted in endo-
plasmic reticulum (ER) stress, which could result in the 
release of Ca2+ from the ER [89–91, 106]. Moreover, Sun 
et al. [110] reported increased store-operated Ca2+ entry 
as another mechanism of action for the activity of Gyps.
Furthermore, Gyps induced dose-dependent DNA 
damage in SAS cells and reduced the expression of sev-
eral DNA repair genes, including ataxia telangiectasia 
mutated, ataxia-telangiectasia and Rad3-related, breast 
cancer gene 1, 14-3-3σ, DNA-dependent serine/threo-
nine protein kinase and p53, in a time-dependent man-
ner. In this way, Gyps treatment stalled the DNA damage 
repair process, forcing the cells to undergo apoptosis 
[109, 111].
Several other components and fractions of GpM have 
also been reported to induce apoptosis. For instance, 
flavonoids [21] and a water extract [112] from GpM 
induced apoptosis in tumor cells via the regulation of the 
Bcl-2 protein family. Furthermore, an ethanolic extract 
from GpM selectively shifted the intracellular H2O2 con-
centration to toxic levels in tumor cells because of the 
increased superoxide dismutase activity of these cells 
compared with healthy cells [113].
Inhibition of invasion and metastasis
Gyps suppressed the invasion and migration of SCC4 
human tongue cancer cells in a dose- and time-depend-
ent manner by downregulating nuclear factor kappa 
B (NF-κB) and matrix metalloproteinase-9 (MMP-9) 
[114]. Gyps also inhibited the invasion and migration 
of SAS cells, as demonstrated by the results of in  vitro 
wound-healing and Boyden Chamber assays. Treatment 
with Gyps led to decreases in the levels of several migra-
tion- and invasion-associated proteins, including NF-κB, 
cyclooxygenase-2, extracellular signal-regulated kinase 
1/2 (ERK1/2), matrix metalloproteinase-2 (MMP-2), 
MMP-9, sevenless homolog, Ras, urokinase-type plas-
minogen activator, focal adhesion kinase and alpha ser-
ine/threonine protein kinase [115]. Furthermore, Gyps 
exhibited anti-migration activities towards SW620 
human colon adenocarcinoma cells and Eca-109 human 
esophageal squamous carcinoma cells [19]. Gyps also 
inhibited the migration of SW-480 human colon adeno-
carcinoma cells in  vitro at a concentration of 100  μg/
mL [36]. This effect was observed in clinical studies. For 
example, patients with advanced malignant tumors that 
were treated with GpM formula showed a reduced can-
cer metastasis rate of 8.5 % compared with 55.2 % in the 
control group [36].
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Glycolysis inhibition
One of the hallmarks of cancer cells is deregulated energy 
metabolism, which can lead to a state known as ‘‘aero-
bic glycolysis’’ [116]. Targeting glucose metabolism has 
therefore proven to be a promising avenue for the devel-
opment of new cancer treatments [117]. GpMix, which 
is a mixture of triterpenoid saponins from GpM, effec-
tively inhibited the growth of cancer cells in the pres-
ence of co-cultivated normal cells [118]. Furthermore, 
GpMix exhibited both chemopreventive and therapeutic 
effects towards the formation of intestinal polyps in Apc-
min/+ mice (a mouse model of colon cancer). Several key 
enzymes along the glycolysis pathway, including pyru-
vate kinase (PK), α-enolase, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), mitochondrial aconitase and 
ATP synthase-α and -β were found to be downregulated 
in R6 cells treated with GpMix by proteomic analysis 
[118]. These findings therefore implied that the inhibition 
of the glycolysis pathway was involved in the suppression 
of cell proliferation by GpMix.
Immune modulation
GpM also exhibited anti-cancer effects indirectly through 
its immunomodulating activities. For example, Yang et al. 
[119] found that a water-soluble polysaccharide from G. 
pentaphyllum herb tea (PSGP) indirectly exerted anti-
cancer activity against SW-1116 human colorectal ade-
nocarcinoma cells and HT-29 by enhancing the immune 
response of macrophages with increased TNF-α secre-
tion in a dose-dependent manner. Moreover, GP-B1, the 
acidic polysaccharide obtained from GpM, not only sig-
nificantly inhibited the growth of cancer cells, but also 
improved cellular immune response with increased levels 
of TNF-α, IFN-γ, IL-10 and IL-12 in the serum of mela-
noma-B16-bearing mice [88]. The anti-cancer activity of 
Gyps was attributed to the elevated immune systems of 
the xenografted mice [120]. Gyps significantly suppressed 
tumor growth in mice transplanted with Lewis lung can-
cer cells with tumor weight inhibition rates of 29.8 ± 1.3, 
51.4  ±  2.2 and 50.0  ±  1.6  % following intraperitoneal 
Gyps injections of 10, 20 and 40  mg/kg, respectively. 
Notably, the immune responses of these mice improved 
considerably, as demonstrated by increases in their total 
splenic cell number and the enhanced biological activities 
of the NK and splenic cells [120]. Clinical studies have 
also shown that GpM enhanced the activity of NK cells in 
breast cancer patients [100], improved the immune func-
tion of cancer patients after chemotherapy, increased the 
T lymphocyte transformation rate and decreased the IgG 
and IgM levels [101].
Perspectives
Numerous studies have been published during the last 
four decades regarding the anti-cancer effects of GpM, 
including reports focused on (i) the isolation and charac-
terization of its chemical components [121, 122]; (ii) the 
evaluation of its anti-cancer activities and mechanisms 
of action [107, 115]; and (iii) studies on its toxicity [96]. 
Taken together, the results of these reports have dem-
onstrated that GpM has a broad anti-cancer spectrum 
(against 30 cancer cell lines, Table  3) without any obvi-
ous inhibitory effect on normal cell proliferation. How-
ever, there are limitations associated with most of these 
studies.
Table 4 In vivo anti-cancer activity of identified GpM components
a The anti-cancer activities of components of GpM are expressed as the percentage of control (readout, dose)
Component Animal model Anti-cancer activitya Reference
Gypenosides Nude mice: xenografted with human oral cancer SAS cells 65.76 % (tumor size, 20 mg/kg for 28 days) [89]
Gypenosides BALB/c mice: injected with human leukemia WEHI-3 cells 150 % (survival rate, 2 mg/kg for 2 weeks)
175 % (survival rate, 4 mg/kg for 2 weeks)
[90]
Gypenosides Nude mice: xenografted with human leukemia HL-60 cells 44 % (tumor size, 20 mg/kg for 28 days) [91]
Gypenosides BALB/c mice: xenografted with murine S180 sarcoma cells 39.57 % (tumor size, 30 mg/kg for 4 days) [92]
Gypenosides BALB/c mice: xenografted with murine colorectal cancer CT-26 
cells
75 % (tumor size, 25 mg/kg for 19 days)
55 % (tumor size, 50 mg/kg for 19 days)
26 % (tumor size, 50 mg/kg + 5 mg/kg 5-Fu for 19 days)
[93]
Gypenosides ApcMin/+ mice: intestinal neoplasia model 66.06 % (polyps number, 500 mg/kg for 4 weeks)
59.92 % (polyps number, 750 mg/kg for 4 weeks)
[94]
Gypenosides ApcMin/+ mice: intestinal neoplasia model 59.32 % (polyps number, 500 mg/kg for 8 weeks) [95]
Polysaccharide BALB/c mice: xenografted with murine S180 sarcoma cells 62.77 % (tumor size, 100 mg/kg for 14 days)
59.24 % (tumor size, 200 mg/kg for 14 days)
[97]
Polysaccharide ICR mice: xenografted with mouse hepatoma H22 cells 62.89 % (tumor size, 50 mg/kg for 10 days)
49.22 % (tumor size, 200 mg/kg for 10 days)
[20]
Page 11 of 16Li et al. Chin Med  (2016) 11:43 
The standard preparation of Gyps needs to be unified
Gyps consist of a mixture of approximately 189 dam-
marane-type saponin glycosides. Most of the studies 
reported to date on GpM have focused exclusively on the 
use of its fractions, such as Gyps, as well as the use of its 
extracts. In contrast, there have been very few reports 
pertaining to the use of single compounds isolated from 
GpM. For example, in all of the papers published dur-
ing the last 15  years regarding the anti-cancer mecha-
nisms of GpM there has only been one study involving 
the use of single compounds. Based on to the lack of 
chemical consistency in the fractions and extracts of 
GpM, greater efforts should be taken to explore the anti-
cancer activities of single compounds derived from GpM 
in future studies, where possible. Moreover, none of the 
Gyps tested in any of the studies reported to date were 
prepared using a unified procedure, which could have 
led to completely different chemical component pro-
files amongst the different samples. Most of these stud-
ies also failed to provide essential chemical composition 
information for their Gyps, such as the exact molecular 
structure of each saponin, the number of saponins in the 
mixture, the relative contents of the different saponins in 
Gyps and a standard HPLC fingerprint [19, 89, 90, 106, 
107, 109, 111, 115]. Studies on the chemical structures 
of the saponins in Gyps are therefore urgently needed, as 
well as further studies towards the chemical composition 
and the quantitative analysis of Gyps. These data would 
allow researchers to develop a deeper understanding of 
the anti-cancer activities and mechanisms of action of 
Gyps and facilitate further studies.
Experimental systems need to be closer to the clinical 
settings
Most of the studies reported to date concerning the 
anti-cancer activities and mechanisms of action of GpM 
have been conducted using in vitro cellular systems. This 
trend could therefore explain why non-specific cell cycle 
arrest and the induction of apoptosis have been cited, 
in the majority of cases, as the principal mechanisms of 
action of GpM [89, 104, 106], with very few reports cit-
ing specific molecular targets or enzymatic pathways. In 
contrast, most of the in vivo studies conducted on GpM, 
have focused on the use of cancer cell lines implanted 
into immunodeficient mice [20, 90, 91]. According to 
this model, cancer cell lines are selected to survive in cul-
ture, and tumor-resident cells and proteins that interact 
with the cancer cells are eliminated to give a phenotypi-
cally homogeneous culture [123]. Patient-derived tumor 
xenograft (PDTX) models have several advantages over 
cell line xenograft models, such as maintaining the het-
erogeneity of the tumor and mimicking the microenvi-
ronment of human tumors [124]. Humanized-xenograft 
models can also be created by co-engrafting a sample of 
a patient-derived tumor together with peripheral blood 
or bone marrow cells into an immunodeficient mouse, 
followed by the reconstitution of the murine immune 
system. Advanced tumor models of this type can be used 
to study the interactions between xenogenic human 
stroma and tumor environments in cancer progression 
and metastasis [125]. Genetically engineered mouse 
models represent an interesting alternative for evaluat-
ing the effects of anti-cancer agents because these ani-
mals maintain a competent immune system, allowing 
for changes in the tumor microenvironment and the 
tumor itself to be thoroughly evaluated from an early 
stage [126]. Based on our review of the literature, we 
believe that further experiments should be performed in 
a PDTX, humanized-xenograft or genetically engineered 
mouse model to evaluate the effects of GpM on tumor 
development with greater clinical accuracy. The latter 
of these two models would be especially interesting in 
terms of evaluating the potential immunomodulatory 
activity of GpM.
Table 5 Clinical uses of GpM
a The anti-cancer activities of components of GpM are expressed as the percentage of control (readout)
Component Patient tumor type Anti-cancer activitya Reference
GpM formula Multiple types 16.44 % (relapse rate)
15.40 % (metastasis rate)
[98]
GpM formula Multiple types 14.23 % (relapse and metastasis rate) [99]
GpM formula Breast cancer 129.56 % (NK cell activity) [100]
GpM formula Multiple types 157 % (T lymphocyte transformation rate)
78.4 % (IgG levels)
75.1 % (IgA levels)
59.9 % (IgM levels)
[101]
GpM formula Lung cancer 128 % (curative rate) [102]
GpM formula Middle-late gastric cancer 163 % (short term curative rate)
140 % (quality of life)
[103]
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Conclusion
In summary, GpM has been investigated extensively as 
a potent anti-cancer agent against many types of can-
cers both in  vitro and in  vivo. The general consensus 
from the literature is that GpM exerts its anti-cancer 
activities through multiple mechanisms, including 
cell cycle arrest, the induction of apoptosis, inhibition 
of invasion and metastasis, glycolysis inhibition and 
immunomodulation.
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